BioSpace News Archive

New momelotinib analysis examining the association between transfusion independence and overall survival to be presented

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4, 2021

OnQuality Pharmaceuticals today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality’s lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting,

Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer Featuring three anti-PD-1 combinations and the continuing evaluation of next-generation BTK inhibitor zanubrutinib

Opdivo plus Yervoy continues to demonstrate a clinically meaningful survival benefit vs. chemotherapy with the longest follow-up of any Phase 3 trial for an immunotherapy combination in non-small cell lung cancer

Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years

Data to highlight promising early efficacy of patritumab deruxtecan in patients with TKI-resistant, EGFR-mutated locally advanced or metastatic non-small cell lung cancer

Data from pivotal KarMMa study to be presented at ASCO21 show 24.8-month median overall survival in triple-class exposed multiple myeloma

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a trials in progress poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021.

Bristol Myers Squibb announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, demonstrating durable improvement in survival with first-line Opdivo plus Yervoy therapy and Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma.